GlassScriptPhysician profile
Parul J Patel
NPI 1942488747
$3,428.45
in general payments reported to CMS, 2019-2025
18 companies · $386 in 2025
The $386 reported for 2025 was more than what a typical Pediatric Endocrinology provider received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $242 · 2020: $704 · 2021: $406 · 2022: $800 · 2023: $489 · 2024: $400 · 2025: $386.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,276.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $569.72 | 2019-2025 | |
| Insulet Corporation | $385.74 | 2019-2022 | |
| Abbvie INC. | $367.95 | 2020-2023 | |
| E.R. Squibb & Sons, L.L.C. | $289.73 | 2023-2024 | Sotyktu |
| Kyowa Kirin, INC. | $239.40 | 2023-2025 | |
| Tandem Diabetes Care, INC. | $231.76 | 2020 | |
| Lilly USA, LLC | $203.32 | 2020-2021 | |
| Amgen INC. | $147.46 | 2025 | Uplizna |
| Abbott Laboratories | $140.01 | 2024 | Freestyle Libre 3 |
| Corcept Therapeutics | $126.67 | 2019 | |
| Ascendis Pharma Endocrinology INC | $125.01 | 2022 | |
| Horizon Therapeutics Plc | $124.97 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $120.06 | 2022 | |
| Sanofi-Aventis U.S. LLC | $114.58 | 2024 | |
| Biomarin Pharmaceutical INC. | $95.13 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $72.07 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $57.14 | 2020-2021 | |
| Endo Pharmaceuticals INC. | $17.73 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parul Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.